Browsing Tag
OrbiMed
8 posts
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
Accro Bioscience raises $50m Series C to advance AC-101 and immune-mediated disease pipeline
Ulcerative colitis needs safer oral options. Accro’s OrbiMed-led raise puts RIPK2 inhibition under a bigger clinical spotlight.
Can the Barinthus–Clywedog merger reshape diabetes and autoimmune drug pipelines?
Barinthus Biotherapeutics merges with Clywedog Therapeutics in an all-stock deal. Explore the impact on diabetes, celiac drug pipelines, and BRNS stock.
Reynold Lemkins Group expands cross-border biotech investments with VISEN Pharmaceuticals (HKEX: 02561) IPO
Reynold Lemkins Group expands cross-border biotech strategy with VISEN Pharmaceuticals (HKEX: 02561) IPO, aligning capital with Asia’s AI-driven healthcare future.
Ironwood Pharmaceuticals to acquire Swiss biotech company VectivBio
Ironwood Pharmaceuticals, a gastrointestinal (GI)-focused healthcare company, has agreed to acquire VectivBio Holding AG, a Switzerland-based biotech company,…
French biotech company Amolyt Pharma Series C round fetches $138m
Amolyt Pharma, a France-based clinical-stage biotechnology company, has secured €130 million (around $138 million) from a Series C…
Chinese biopharma company Akeso raises $150m for antibody drug discovery
Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas,…
Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment
Galecto Biotech, a Denmark-based pharmaceutical company specializing in galectin modulators for severe diseases like idiopathic pulmonary fibrosis (IPF)…